Last updated: February 13, 2026
Summary
NDC 00054-0710 corresponds to a specific formulation of Liraglutide, marketed as Victoza by Novo Nordisk. Its primary indication includes type 2 diabetes mellitus, with recent expansion into obesity treatment under Saxenda. The drug remains a key player in incretin-based therapies with consistent demand in diabetes management. The overall market is projected to grow driven by increasing diabetes prevalence and expanded indications, influencing future pricing strategies.
Current Market Landscape
Product Profile
- Formulation: Liraglutide injectable (3 mL pen)
- Indications: Type 2 diabetes; obesity (under Saxenda)
- Strengths: 6 mg/mL dosage, administered once daily
- Brand: Victoza (Novo Nordisk)
Market Presence
Victoza commands significant market share in the GLP-1 receptor agonist class. It competes with drugs like Trulicity (Eli Lilly), Ozempic (Novo Nordisk), and Mounjaro (Eli Lilly). As of 2022, Victoza maintains approximately 20-25% share in the GLP-1 class for diabetes (IQVIA data).
Regulatory Milestones
- FDA approval for diabetes (2010)
- Expanded label for obesity (Saxenda, approved 2014)
- Ongoing trials for cardiovascular benefits and additional indications
Market Size and Growth Drivers
| Metric |
2022 Data |
Projected 2027 |
Notes |
| Global diabetes treatment market |
$60 billion |
$75 billion |
CAGR ~4.8% |
| GLP-1 receptor agonist segment |
~$18 billion |
$30 billion |
CAGR ~11.4% |
| Victoza sales (marketed by Novo Nordisk) |
$3.0 billion (2022) |
$4.1 billion |
Slight deceleration due to biosimilar threats |
Demand accelerates from rising diabetes prevalence (~10.5% global prevalence in 2022, WHO) and obesity rates (~13% worldwide). The approval of once-weekly formulations (Ozempic, Trulicity) pressures Victoza's market share but sustains its relevance through established clinician familiarity.
Competitive Dynamics
- Ozempic (semaglutide): Higher efficacy in weight reduction, longer dosing intervals.
- Trulicity: Similar profile, with strong adherence benefits.
- Mounjaro: Emerging as a potent option with dual mechanisms.
Victoza benefits from established safety data and clinician preference but faces pricing pressures from newer agents with superior convenience and efficacy profiles.
Pricing Trends and Projections
Current Pricing
- List Price (U.S.): Approximately $880 for a 3 mL pen (~30 days of therapy) (GoodRx, 2023).
- Average Wholesale Price (AWP): ~$1,000.
- Actual out-of-pocket costs vary depending on insurance coverage; copays for insured patients typically range from $25 to $75 monthly.
Reimbursement and Payer Dynamics
- Insurers increasingly scrutinize high-cost agents; formularies favor biosimilars when available or favor cheaper alternatives.
- Price reductions linked to contract negotiations and biosimilar entries anticipated in mid-2020s, potentially lowering net prices by 15-25%.
| Future Price Projections (2023–2027) |
Year |
Estimated List Price |
Expected Price Adjustment |
Rationale |
| 2023 |
$880 |
0% |
Stable year with ongoing demand |
| 2024 |
$860 |
-2% |
Market stabilization; patent protections remain intact |
| 2025 |
$820 |
-5% |
Potential biosimilar competition materializes |
| 2026 |
$780 |
-5% |
Increased biosimilar availability; payer pressure intensifies |
| 2027 |
$750 |
-4% |
Competitive pricing pressures in place |
Note: Price reductions are primarily driven by biosimilar market entry, negotiations, and market share shifts.
Biosimilar Impact and Patent Landscape
Patent Status
- Victoza's primary patents expired or will expire by 2024/2025, exposing the drug to biosimilar competition.
- Several biosimilar candidates are developing, aiming for approval by mid-2020s.
Biosimilar Pricing Impact
- Biosimilar versions are expected to be priced 15-30% below originator prices.
- Price erosion may lead to a 20-40% reduction in net revenue for Victoza by 2026.
Market Entry Risks
- Biosimilars may face regulatory hurdles depending on regional approval timelines.
- Key markets like the U.S., EU, and Japan are primary targets for biosimilar launches.
Regulatory and Policy Influences
- Price negotiations: CMS and private insurers increasingly leverage formulary management to lower drug costs.
- Value-based agreements: Some payers seek outcomes-based contracts, possibly reducing effective prices.
- Global pricing: Countries like Canada and Australia impose price caps, influencing U.S. pricing strategies through parallel import and market pressure.
Implications for Stakeholders
- Pharmaceutical companies: Innovator firms must balance patent strategies with biosimilar competition, considering lifecycle management and line extension initiatives.
- Investors: Potential declines in net prices highlight the necessity to assess biosimilar timelines and market penetration rates.
- Healthcare providers: A shift towards newer agents with better convenience may further erode Victoza's market share and justify reevaluating prescribing practices.
Key Takeaways
- NDC 00054-0710 (Victoza) remains a vital diabetes therapy with stable demand but faces long-term pricing pressure from biosimilars.
- The global market for GLP-1 receptor agonists continues to expand at double-digit CAGR, driven by both diabetes and obesity indications.
- Shipments and revenues are projected to moderate from 2024 onward due to biosimilar competition and payer negotiation strategies, with list prices declining gradually.
- Patent expirations around 2024-2025 are pivotal, potentially accelerating biosimilar entry and cost reductions.
- Multinational policies and insurance dynamics significantly influence net pricing and market access.
FAQs
1. When will biosimilars for Victoza likely enter the market?
Biosimilar approval is anticipated around 2024-2025, contingent on regional regulatory processes and patent litigation outcomes.
2. How will biosimilar competition affect Victoza's market share?
Biosimilar entry could reduce Victoza's market share by 10-20% in the first two years, with further erosion possible if newer, more convenient therapies gain preference.
3. Are there major regional differences in pricing strategies?
Yes. The U.S. maintains higher nominal list prices with substantial rebates, while countries with price caps (e.g., Canada, Australia) impose lower net prices through negotiations.
4. Do new formulations or indications impact price projections?
Yes. Once-weekly formulations or additional approvals (e.g., cardiovascular benefits) may sustain demand and stabilize prices temporarily.
5. What are the key risks to the price projections?
Biosimilar market entry, regulatory actions, and payer negotiations represent primary risks that could further depress prices or accelerate market share decline.
Citations
[1] IQVIA. Market Trends in Diabetes and GLP-1 Receptor Agonists, 2022.
[2] GoodRx. Drug Pricing Data, 2023.
[3] FDA. Victoza Label and Approval History, 2010-2022.
[4] Novo Nordisk Annual Reports, 2022.
[5] World Health Organization. Diabetes Prevalence Statistics, 2022.
